ClinicalTrials.gg
CompletedNCT04442269Updated Apr 4, 2025Results posted

Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)

A Phase 2 interventional study of dupilumab and Placebo in Allergic Bronchopulmonary Aspergillosis, sponsored by Regeneron Pharmaceuticals. Completed at 50 sites in 10 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-04-04.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Aspergillosis, Allergic Bronchopulmonary with a site in United States — none open to participants now, none under way, none of them phase 3. Aspergillosis, Allergic Bronchopulmonary · United States.

Started
2020
the only one that year
Phase 2
3 of 10
none open now
Registered
8th of 10
by date
Lead sponsor
1 of 10
Regeneron Pharmaceuticals

Among the 10 studies in Aspergillosis, Allergic Bronchopulmonary with a site in United States, this one is the only one that started in 2020, is one of 3 in phase 2, and was the 8th registered.

Aspergillosis, Allergic Bronchopulmonary

42 studies on the registry are indexed under Aspergillosis, Allergic Bronchopulmonary; 13 are open to participants now.

Browse Aspergillosis, Allergic Bronchopulmonary studies →

Open to participants now

None of the 10 studies in Aspergillosis, Allergic Bronchopulmonary with a site in United States is open now. The open studies under Aspergillosis, Allergic Bronchopulmonary, anywhere →

Who these studies take

Of the 10 Aspergillosis, Allergic Bronchopulmonary studies recruiting now, 7 (70%) set no upper age limit and 1 (10%) stops at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Aspergillosis, Allergic Bronchopulmonary with a site in United States as a file.
02

Study summary

The primary objective of the study is to evaluate the efficacy of dupilumab on lung function in participants with Allergic Bronchopulmonary Aspergillosis (ABPA).

The secondary objectives of the study are:

  • To evaluate the effects of dupilumab on exacerbations in participants with ABPA
  • To evaluate the effects of dupilumab on ABPA-related exacerbations
  • To evaluate the effects of dupilumab on hospitalization/emergency department (ED)/urgent care visits in participants with ABPA
  • To evaluate the effects of dupilumab on asthma control in participants with ABPA
  • To evaluate the effects of dupilumab on health-related quality of life (HRQoL) in participants with ABPA
  • To evaluate the effects of dupilumab on serum total immunoglobulin E (IgE) and Aspergillus-specific IgE concentrations
  • To evaluate the effects of dupilumab on Fractional exhaled Nitric Oxide (FeNO) levels
  • To evaluate safety and tolerability of dupilumab in participants with ABPA
  • To evaluate dupilumab concentrations in serum and the incidence of anti-dupilumab antibodies in participants with ABPA
03

Conditions studied

  • Allergic Bronchopulmonary Aspergillosis
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosis of both ABPA and asthma
  • On a maintenance therapy for their asthma with controller medication which must include inhaled (ICS) and may include 1 or more additional controller medications including a long-acting beta agonist (LABA), leukotriene receptor antagonist (LTRA), and/or long-acting muscarinic receptor antagonist (LAMA), etc for at least 12 weeks, with a stable dose and regimen with no change in the dose or frequency of administration for at least 4 weeks prior to the screening visit and between the screening and baseline/randomization visits
  • For participants on OCS (oral corticosteroid): must be on a chronic stable dose (no change in the dose) of OCS of up to 10 mg/day (for participants taking daily corticosteroids) or up to 30 mg every alternate day (for participants taking alternate day corticosteroids) (prednisone/prednisolone or the equivalent) for at least 4 weeks prior to the screening visit and between the screening and the baseline/randomization visit
  • Must have experienced ≥1 severe respiratory exacerbation requiring treatment with systemic corticosteroids or hospitalization or treatment in ED/urgent care within 12 months prior to the screening visit or must be receiving chronic stable low-dose OCS per above criteria

Key Exclusion Criteria:

  • Weight less than 30.0 kilograms
  • Current smoker or e-cigarette user, cessation of smoking or e-cigarette use within 6 months prior to randomization, or >=10 pack-years smoking history
  • Post-bronchodilator \<30% predicted normal at screening
  • Respiratory exacerbation requiring systemic corticosteroids within 4 weeks prior to screening and between screening and baseline visit (for patients on daily or alternate day OCS, exacerbation requiring at least double the maintenance dose of corticosteroids)
  • Upper or lower respiratory tract infection within the 4 weeks prior to screening (visit 1) or between the screening and randomization visits
  • Significant chronic pulmonary disease other than asthma complicated with ABPA (eg, physician-diagnosed bronchiectasis due to a condition other than ABPA; cystic fibrosis; sarcoidosis; interstitial lung disease not due to ABPA; [COPD] not due to ABPA; hypereosinophilic syndrome; etc), a diagnosed pulmonary or systemic disease associated with elevated peripheral eosinophil counts
  • Diagnosis or suspected diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA) (also called Churg-Strauss Syndrome)

NOTE: Other protocol defined inclusion / exclusion criteria applies.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    dupilumab

    Loading subcutaneous (SC) dose on day 1, followed by SC dose, every two weeks (Q2W)

    Drug: dupilumab

  • Experimental
    Placebo

    Matching dupilumab without active substance

    Drug: Placebo

Interventions

  • Single-use prefilled glass syringe administered by subcutaneous (SC) injection.

    Also known as: • DUPIXENT, • REGN668, • SAR231893

  • DrugPlacebo

    Matching placebo

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) Compared to Placebo

    Time frame: At Week 24

Secondary outcomes

  1. Annualized Rate of ABPA-related Exacerbations

    Defined as severe respiratory exacerbations that are associated with a doubling of serum total Immunoglobulin E (IgE) from the prior pre-exacerbation value. Adjusted Rate: Negative Binomial Regression Model Unadjusted Rate: (Number of events)/(number of participant years)

    Time frame: Over the 24 to 52 Week Treatment Period

  2. Annualized Rate of Severe Respiratory Exacerbations

    Defined as new onset of symptoms or clinical worsening of respiratory symptoms requiring systemic corticosteroid treatment for ≥3 consecutive days; for participants who are on maintenance systemic corticosteroids, at least double the dose of maintenance systemic corticosteroids for ≥3 consecutive days (with or without antibiotic therapy if indicated) Adjusted Rate: Negative Binomial Regression Model Unadjusted Rate: (Number of events)/(number of participant years)

    Time frame: Over the 24 to 52 Week Treatment Period

  3. Annualized Rate of Severe Respiratory Exacerbations Requiring Either Hospitalization or Observation for >24 Hours in an ED/Urgent Care Facility

    Annualized rate of severe respiratory exacerbations requiring either hospitalization or observation for \>24 hours in an emergency department/urgent care facility (events per person-year) Adjusted Rate: Negative Binomial Regression Model Unadjusted Rate: (Number of events)/(number of participant years)

    Time frame: Over the 24 to 52 Week Treatment Period

  4. Change From Baseline in Asthma Control Questionnaire (ACQ)-5 Score

    ACQ is completed by patient to measure both the adequacy of asthma control and change in asthma control, which occurs either spontaneously or as a result of treatment. The ACQ-5 score is the mean of the first 5 questions, between 0 (totally controlled) and 6 (severely uncontrolled). A higher score indicates lower asthma control. Participants with a score below 1.0 reflect adequately controlled asthma and participants with scores above 1.0 reflect inadequately controlled asthma. The optimal cut-point score of 1.50 should be used to be confident that a patient has inadequately controlled asthma.

    Time frame: Over the 24 to 52 Week Treatment Period

  5. Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score

    SGRQ will be completed by the patient to measure and quantify health status in adult participants with chronic airflow limitation. Total score ranges from 0 to 100. Scores by dimension are calculated for three domains: Symptoms, Activity, and Impacts (Psychosocial). Lower score indicates better Quality of Life (QoL).

    Time frame: Over the 24 to 52 Week Treatment Period

  6. Percentage of Participants Achieving a Reduction in the SGRQ Total Score of 4 Points or Greater From Baseline

    SGRQ will be completed by the patient to measure and quantify health status in adult participants with chronic airflow limitation. Total score ranges from 0 to 100. Scores by dimension are calculated for three domains: Symptoms, Activity, and Impacts (Psychosocial). Lower score indicates better Quality of Life (QoL).

    Time frame: Up to 52 Weeks

  7. Percent Change From Baseline in Total IgE in Serum

    Time frame: Over the 24 to 52 Week Treatment Period

  8. Percent Change From Baseline in A Fumigatus-specific IgE in Serum

    Time frame: Over the 24 to 52 Week Treatment Period

  9. Absolute Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO)

    Time frame: Over the 24 to 52 Week Treatment Period

  10. Percent Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO)

    Time frame: Over the 24 to 52 Week Treatment Period

  11. Number of Participants With Treatment-emergent Adverse Events (TEAEs) From Baseline

    Time frame: Through the end of the 52 Week Treatment Period

  12. Number of Participants With Treatment-emergent Anti-drug Antibody (ADA) Responses and Titer Over Time

    Time frame: Up to 64 Weeks

  13. Concentrations of Functional Dupilumab in Serum by Treatment Regimen

    Time frame: Up to 64 Weeks

07

Results

Posted Aug 21, 2024

Participant flow

Participant flow — Overall Study
MilestonePlaceboDupilumab 300 mg Q2W
Started2735
Completed2029
Not completed76
Withdrew: Adverse event10
Withdrew: Death01
Withdrew: Decision by the investigator/sponsor11
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject32
Withdrew: Protocol deviation01
Withdrew: Travel limitations11

Outcome measures

PrimaryChange From Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) Compared to Placebo
Time frame:
At Week 24
Reported as:
Least squares mean · Liters
Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) Compared to Placebo
LitersPlaceboDupilumab 300 mg Q2W
Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) Compared to Placebo0.002 ± 0.05580.203 ± 0.0482
Statistical analysis
  • Placebo vs Dupilumab 300 mg Q2W · Mixed Models Analysis · p = 0.0022 · Mean difference: 0.201 · 95% CI 0.0768 to 0.3256
SecondaryAnnualized Rate of ABPA-related Exacerbations

Defined as severe respiratory exacerbations that are associated with a doubling of serum total Immunoglobulin E (IgE) from the prior pre-exacerbation value. Adjusted Rate: Negative Binomial Regression Model Unadjusted Rate: (Number of events)/(number of participant years)

Time frame:
Over the 24 to 52 Week Treatment Period
Reported as:
Number · Events per person-year
Annualized Rate of ABPA-related Exacerbations
Events per person-yearPlaceboDupilumab 300 mg Q2W
Adjusted RateNA (NA to NA)NA (NA to NA)
Unadjusted Rate0 (0 to 0)0 (0 to 0)
SecondaryAnnualized Rate of Severe Respiratory Exacerbations

Defined as new onset of symptoms or clinical worsening of respiratory symptoms requiring systemic corticosteroid treatment for ≥3 consecutive days; for participants who are on maintenance systemic corticosteroids, at least double the dose of maintenance systemic corticosteroids for ≥3 consecutive days (with or without antibiotic therapy if indicated) Adjusted Rate: Negative Binomial Regression Model Unadjusted Rate: (Number of events)/(number of participant years)

Time frame:
Over the 24 to 52 Week Treatment Period
Reported as:
Number · Events per person year
Annualized Rate of Severe Respiratory Exacerbations
Events per person yearPlaceboDupilumab 300 mg Q2W
Adjusted Rate1.5510.695
Unadjusted Rate0.9430.545
SecondaryAnnualized Rate of Severe Respiratory Exacerbations Requiring Either Hospitalization or Observation for >24 Hours in an ED/Urgent Care Facility

Annualized rate of severe respiratory exacerbations requiring either hospitalization or observation for \>24 hours in an emergency department/urgent care facility (events per person-year) Adjusted Rate: Negative Binomial Regression Model Unadjusted Rate: (Number of events)/(number of participant years)

Time frame:
Over the 24 to 52 Week Treatment Period
Reported as:
Number · Events per person year
Annualized Rate of Severe Respiratory Exacerbations Requiring Either Hospitalization or Observation for >24 Hours in an ED/Urgent Care Facility
Events per person yearPlaceboDupilumab 300 mg Q2W
Adjusted RateNANA
Unadjusted Rate0.0410.128
SecondaryChange From Baseline in Asthma Control Questionnaire (ACQ)-5 Score

ACQ is completed by patient to measure both the adequacy of asthma control and change in asthma control, which occurs either spontaneously or as a result of treatment. The ACQ-5 score is the mean of the first 5 questions, between 0 (totally controlled) and 6 (severely uncontrolled). A higher score indicates lower asthma control. Participants with a score below 1.0 reflect adequately controlled asthma and participants with scores above 1.0 reflect inadequately controlled asthma. The optimal cut-point score of 1.50 should be used to be confident that a patient has inadequately controlled asthma.

Time frame:
Over the 24 to 52 Week Treatment Period
Reported as:
Mean · ACQ-5 Score
Change From Baseline in Asthma Control Questionnaire (ACQ)-5 Score
ACQ-5 ScorePlaceboDupilumab 300 mg Q2W
Week 24-1.10 ± 1.102-1.24 ± 1.081
Week 36-0.81 ± 0.878-1.15 ± 1.208
Week 44-0.87 ± 1.233-1.01 ± 1.359
Week 52-0.84 ± 1.183-1.29 ± 1.241
SecondaryChange From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score

SGRQ will be completed by the patient to measure and quantify health status in adult participants with chronic airflow limitation. Total score ranges from 0 to 100. Scores by dimension are calculated for three domains: Symptoms, Activity, and Impacts (Psychosocial). Lower score indicates better Quality of Life (QoL).

Time frame:
Over the 24 to 52 Week Treatment Period
Reported as:
Mean · SGRQ Total Score
Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score
SGRQ Total ScorePlaceboDupilumab 300 mg Q2W
Week 12-9.463 ± 16.3993-17.956 ± 14.6184
Week 24-7.626 ± 14.5412-23.079 ± 15.9104
Week 36-8.796 ± 16.4257-20.178 ± 15.5266
Week 52-8.938 ± 15.3127-25.309 ± 20.1035
SecondaryPercentage of Participants Achieving a Reduction in the SGRQ Total Score of 4 Points or Greater From Baseline

SGRQ will be completed by the patient to measure and quantify health status in adult participants with chronic airflow limitation. Total score ranges from 0 to 100. Scores by dimension are calculated for three domains: Symptoms, Activity, and Impacts (Psychosocial). Lower score indicates better Quality of Life (QoL).

Time frame:
Up to 52 Weeks
Reported as:
Number · Percent
Percentage of Participants Achieving a Reduction in the SGRQ Total Score of 4 Points or Greater From Baseline
PercentPlaceboDupilumab 300 mg Q2W
Week 1250.0 (30.72 to 69.28)85.3 (69.87 to 93.55)
Week 2463.6 (42.95 to 80.27)87.1 (71.15 to 94.87)
Week 3657.1 (36.55 to 75.53)86.2 (69.44 to 94.50)
Week 5268.4 (46.01 to 84.64)89.3 (72.80 to 96.29)
SecondaryPercent Change From Baseline in Total IgE in Serum
Time frame:
Over the 24 to 52 Week Treatment Period
Reported as:
Mean · Percent
Percent Change From Baseline in Total IgE in Serum
PercentPlaceboDupilumab 300 mg Q2W
Week 24-0.665 ± 40.2236-47.245 ± 19.4110
Week 36-5.945 ± 27.6767-57.752 ± 18.0812
Week 52-2.767 ± 42.8914-62.175 ± 17.0285
SecondaryPercent Change From Baseline in A Fumigatus-specific IgE in Serum
Time frame:
Over the 24 to 52 Week Treatment Period
Reported as:
Mean · Percent
Percent Change From Baseline in A Fumigatus-specific IgE in Serum
PercentPlaceboDupilumab 300 mg Q2W
Week 240.099 ± 39.7612-39.859 ± 25.3095
Week 366.766 ± 39.9041-45.654 ± 26.7915
Week 5212.618 ± 94.6306-49.126 ± 30.6790
SecondaryAbsolute Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO)
Time frame:
Over the 24 to 52 Week Treatment Period
Reported as:
Mean · ppb
Absolute Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO)
ppbPlaceboDupilumab 300 mg Q2W
Week 24-4.80 ± 23.521-22.04 ± 38.410
Week 363.11 ± 20.571-21.48 ± 40.538
Week 441.38 ± 21.896-19.18 ± 37.122
Week 52-4.79 ± 27.634-19.04 ± 35.471
SecondaryPercent Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO)
Time frame:
Over the 24 to 52 Week Treatment Period
Reported as:
Mean · Percent
Percent Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO)
PercentPlaceboDupilumab 300 mg Q2W
Week 241.67 ± 44.069-29.91 ± 32.527
Week 3619.80 ± 44.053-24.56 ± 43.975
Week 4415.43 ± 54.887-19.83 ± 48.308
Week 522.55 ± 56.506-20.35 ± 48.100
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) From Baseline
Time frame:
Through the end of the 52 Week Treatment Period
Reported as:
Number · Participants with TEAEs
Number of Participants With Treatment-emergent Adverse Events (TEAEs) From Baseline
Participants with TEAEsPlaceboDupilumab 300 mg Q2W
Number of Participants With Treatment-emergent Adverse Events (TEAEs) From Baseline2230
SecondaryNumber of Participants With Treatment-emergent Anti-drug Antibody (ADA) Responses and Titer Over Time
Time frame:
Up to 64 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Anti-drug Antibody (ADA) Responses and Titer Over Time
ParticipantsPlaceboDupilumab 300 mg Q2W
TE & TB Maximum Titer Category Low (<1,000)01
TE & TB Maximum Titer Category Moderate (1,000 to 10,000)00
TE & TB Maximum Titer Category High (>10,000)00
SecondaryConcentrations of Functional Dupilumab in Serum by Treatment Regimen
Time frame:
Up to 64 Weeks
Reported as:
Mean · mg/L
Concentrations of Functional Dupilumab in Serum by Treatment Regimen
mg/LDupilumab 300 mg Q2W
Week 00 ± 0
Week 1263.8 ± 35.4
Week 2486.5 ± 53.6
Week 5282.2 ± 55.4
Week 641.67 ± 4.38

Adverse events

Collected over From Day 1 to EOS (End Of Study) visit ~(up to 64 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo1/27 (3.7%)5/27 (18.5%)19/27 (70.4%)
Dupilumab 300 mg Q2W1/35 (2.9%)3/35 (8.6%)29/35 (82.9%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventPlaceboDupilumab 300 mg Q2W
InfluenzaInfections and infestations0/272/35
Pneumonia bacterialInfections and infestations0/272/35
Bronchopulmonary aspergillosis allergicInfections and infestations1/270/35
Lower respiratory tract infectionInfections and infestations1/270/35
PneumoniaInfections and infestations1/270/35
Trisomy 16Congenital, familial and genetic disorders1/270/35
Pelvic fractureInjury, poisoning and procedural complications1/270/35
Oesophageal carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/270/35
Pancreatic carcinoma metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/270/35
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/270/35
Most frequent other events
Showing 10 of 34
Most frequent other events
EventPlaceboDupilumab 300 mg Q2W
Respiratory disorderRespiratory, thoracic and mediastinal disorders9/274/35
ArthralgiaMusculoskeletal and connective tissue disorders0/278/35
COVID-19Infections and infestations3/276/35
HeadacheNervous system disorders2/276/35
Upper respiratory tract infectionInfections and infestations1/274/35
Urinary tract infectionInfections and infestations0/274/35
Injection site erythemaGeneral disorders0/274/35
AsthmaRespiratory, thoracic and mediastinal disorders3/274/35
CoughRespiratory, thoracic and mediastinal disorders1/274/35
Respiratory tract infection bacterialInfections and infestations3/270/35

Baseline characteristics

Age, Customized
Age, Customized(years)PlaceboDupilumab 300 mg Q2WTotal
Mean57.1 ± 14.3861.2 ± 8.6259.4 ± 11.56
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboDupilumab 300 mg Q2WTotal
Female172239
Male101323
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboDupilumab 300 mg Q2WTotal
Hispanic or Latino246
Not Hispanic or Latino242953
Unknown or Not Reported123
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboDupilumab 300 mg Q2WTotal
White252853
Asian145
Other011
Not Reported123
08

Study locations

50 sites
  • Regeneron Study Site
    Birmingham, Alabama 35209, United States
  • Regeneron Study Site
    Scottsdale, Arizona 85251, United States
  • Regeneron Study Site
    Bakersfield, California 93301, United States
  • Regeneron Study Site
    La Jolla, California 92093, United States
  • Regeneron Study Site
    Los Angeles, California 90025, United States
  • Regeneron Study Site
    Riverside, California 92506, United States
  • Regeneron Study Site
    Boise, Idaho 83706, United States
  • Regeneron Study Site
    Iowa City, Iowa 52242, United States
  • Regeneron Study Site
    Bronx, New York 10461, United States
  • Regeneron Study Site
    New York, New York 10032, United States
  • Regeneron Study Site
    Columbus, Ohio 43235, United States
  • Regeneron Study Site
    DuBois, Pennsylvania 15801, United States
  • Regeneron Study Site
    Philadelphia, Pennsylvania 19140, United States
  • Regeneron Study Site
    Haskovo, 6305, Bulgaria
  • Regeneron Study Site
    Razgrad, 7200, Bulgaria
  • Regeneron Study Site
    Smolyan, 4700, Bulgaria
  • Regeneron Study Site
    Sofia, 1142, Bulgaria
  • Regeneron Study Site
    Brest, 29609, France
  • Regeneron Study Site
    Lyon, 69004, France
  • Regeneron Study Site
    Marseille, 13015, France
  • Regeneron Study Site
    Montpellier, 34295, France
  • Regeneron Study Site
    Paris, 75018, France
  • Regeneron Study Site
    Rennes, 35033, France
  • Regeneron Study Site
    Tours, 37044, France
  • Regeneron Study Site
    Leipzig, Saxony 4357, Germany
  • Regeneron Study Site
    Berlin, 10717, Germany
  • Regeneron Study Site
    Frankfurt am Main, 60389, Germany
  • Regeneron Study Site
    Budapest, 1083, Hungary
  • Regeneron Study Site
    Fukuyama, 7200001, Japan
  • Regeneron Study Site
    Kanagawa, 259-1193, Japan
  • Regeneron Study Site
    Nagoya, 454-8509, Japan
  • Regeneron Study Site
    Naka-gun, 3191113, Japan
  • Regeneron Study Site
    Sakai, 591-8555, Japan
  • Regeneron Study Site
    Yanagawa, 8320059, Japan
  • Regeneron Study Site
    Yokohama, 231-8682, Japan
  • Regeneron Study Site
    Amsterdam, North Holland 1105AZ, Netherlands
  • Regeneron Study Site
    Arnhem, 6815, Netherlands
  • Regeneron Study Site
    Breda, 4818 CK, Netherlands
  • Regeneron Study Site
    Eindhoven, 5623, Netherlands
  • Regeneron Study Site
    Zutphen, 7207, Netherlands
  • Regeneron Study Site
    Bialystok, 15-044, Poland
  • Regeneron Study Site
    Gdansk, 80402, Poland
  • Regeneron Study Site
    Oradea, Bihor 410169, Romania
  • Regeneron Study Site
    Brasov, 500051, Romania
  • Regeneron Study Site
    Leicester, England LE39QP, United Kingdom
  • Regeneron Study Site
    Liverpool, England L7 8XP, United Kingdom
  • Regeneron Study Site
    London, England E1 2EF, United Kingdom
  • Regeneron Study Site
    London, England SW3 6NP, United Kingdom
  • Regeneron Study Site
    Wythenshawe, England M23 9LT, United Kingdom
  • Regeneron Study Site
    Bradford, West Yorkshire BD96RJ, United Kingdom
09

References and documents

Publications

  • Kao CC, Hanania NA, Parulekar AD. The impact of fungal allergic sensitization on asthma. Curr Opin Pulm Med. 2021 Jan;27(1):3-8. doi: 10.1097/MCP.0000000000000740. PubMed 33027187 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.

Access criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Jul 2023, 34 months.

Results were first posted in Aug 2024, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2020
First posted
Jun 22, 2020
StartActual
Sep 15, 2020
Primary completionActual
Jul 27, 2023
CompletionActual
Feb 9, 2024
Results first posted
Aug 21, 2024
Last update
Apr 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04442269
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Jun 22, 2020
Start date
Sep 15, 2020
Primary completion
Jul 27, 2023
Completion
Feb 9, 2024
Results posted
Aug 21, 2024
Last update
Apr 4, 2025

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion